Macrogen Inc (038290) - Total Liabilities
Based on the latest financial reports, Macrogen Inc (038290) has total liabilities worth ₩173.25 Billion KRW (≈ $117.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Macrogen Inc equity growth rate to track the company's year-over-year net asset growth rate.
Macrogen Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Macrogen Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Macrogen Inc to measure how efficiently the company converts operating cash flow to free cash.
Macrogen Inc Competitors by Total Liabilities
The table below lists competitors of Macrogen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Morn Sun Feed Mill Corp
TWO:1240
|
Taiwan | NT$631.07 Million |
|
NEOOTO Co. Ltd
KQ:212560
|
Korea | ₩70.52 Billion |
|
ALT5 Sigma Corporation
NASDAQ:ALTS
|
USA | $66.46 Million |
|
Rimbunan Sawit Bhd
KLSE:5113
|
Malaysia | RM390.61 Million |
|
South West Pinnacle Exploration Limited
NSE:SOUTHWEST
|
India | Rs1.29 Billion |
|
Suny Cellular Communication Ltd
TA:SNCM
|
Israel | ILA208.69 Million |
|
Mono Next Public Company Limited
BK:MONO
|
Thailand | ฿2.55 Billion |
|
JEIO CO LTD (PROPOSED)
KQ:418550
|
Korea | ₩40.00 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Macrogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 038290 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Macrogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Macrogen Inc (2011–2024)
The table below shows the annual total liabilities of Macrogen Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩152.23 Billion ≈ $103.17 Million |
+54.35% |
| 2023-12-31 | ₩98.63 Billion ≈ $66.84 Million |
-2.16% |
| 2022-12-31 | ₩100.80 Billion ≈ $68.31 Million |
+0.27% |
| 2021-12-31 | ₩100.53 Billion ≈ $68.13 Million |
+12.15% |
| 2020-12-31 | ₩89.64 Billion ≈ $60.75 Million |
-20.11% |
| 2019-12-31 | ₩112.20 Billion ≈ $76.04 Million |
+82.48% |
| 2018-12-31 | ₩61.49 Billion ≈ $41.67 Million |
-27.17% |
| 2017-12-31 | ₩84.43 Billion ≈ $57.22 Million |
+9.69% |
| 2016-12-31 | ₩76.97 Billion ≈ $52.16 Million |
+32.26% |
| 2015-12-31 | ₩58.20 Billion ≈ $39.44 Million |
+18.66% |
| 2014-12-31 | ₩49.05 Billion ≈ $33.24 Million |
+77.29% |
| 2013-12-31 | ₩27.66 Billion ≈ $18.75 Million |
-9.02% |
| 2012-12-31 | ₩30.41 Billion ≈ $20.61 Million |
+107.57% |
| 2011-12-31 | ₩14.65 Billion ≈ $9.93 Million |
-- |
About Macrogen Inc
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more